Literature DB >> 19495814

Bisphosphonate-associated osteonecrosis of the jaw: what do we currently know? A survey of knowledge given in the recent literature.

Jan Rustemeyer1, Andreas Bremerich.   

Abstract

Increasing application of bisphosphonates for therapy of osteopathies has led to reports of the severe associated adverse effects of osteonecrosis of the jaw (ONJ). We reviewed recent literature to assess several aspects of bisphosphonate-associated ONJ, and to provide healthcare professionals with an overview of treatment and preventive options. Literature databases were searched using keywords. Information of 54 articles were discussed and completed by additional literature. High-risk factors were application of nitrogen-containing bisphosphonates, teeth extractions, and ill-fitting dentures. Treatment included non-surgical options and radical surgery. Success and failure were described for all treatment options; further studies investigating long-term recovery and recurrence are warranted. Paying attention to effective prevention of ONJ before, during, and after treatment is essential.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19495814     DOI: 10.1007/s00784-009-0294-0

Source DB:  PubMed          Journal:  Clin Oral Investig        ISSN: 1432-6981            Impact factor:   3.573


  64 in total

1.  Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management.

Authors:  Salvatore L Ruggiero; John Fantasia; Eric Carlson
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  2006-07-31

2.  Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy.

Authors:  Cesar A Migliorati; Mark M Schubert; Douglas E Peterson; Luis Marcelo Seneda
Journal:  Cancer       Date:  2005-07-01       Impact factor: 6.860

3.  Bisphosphonate-associated osteonecrosis of the jaws: a review of current knowledge.

Authors:  Michael R Markiewicz; Joseph E Margarone; John H Campbell; Alfredo Aguirre
Journal:  J Am Dent Assoc       Date:  2005-12       Impact factor: 3.634

4.  Assessment of renal toxicity and osteonecrosis of the jaws in patients receiving zoledronic acid for bone metastasis.

Authors:  D Aguiar Bujanda; U Bohn Sarmiento; M A Cabrera Suárez; J Aguiar Morales
Journal:  Ann Oncol       Date:  2006-11-02       Impact factor: 32.976

5.  American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma.

Authors:  James R Berenson; Bruce E Hillner; Robert A Kyle; Ken Anderson; Allan Lipton; Gary C Yee; J Sybil Biermann
Journal:  J Clin Oncol       Date:  2002-09-01       Impact factor: 44.544

6.  Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients.

Authors:  Daniele Santini; Bruno Vincenzi; Giordano Dicuonzo; Giuseppe Avvisati; Cristian Massacesi; Fabrizio Battistoni; Michele Gavasci; Laura Rocci; Maria Cristina Tirindelli; Vittorio Altomare; Massimo Tocchini; Maurizio Bonsignori; Giuseppe Tonini
Journal:  Clin Cancer Res       Date:  2003-08-01       Impact factor: 12.531

Review 7.  Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer.

Authors:  J R Ross; Y Saunders; P M Edmonds; S Patel; K E Broadley; S R D Johnston
Journal:  BMJ       Date:  2003-08-30

8.  Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix.

Authors:  P M Boonekamp; L J van der Wee-Pals; M M van Wijk-van Lennep; C W Thesing; O L Bijvoet
Journal:  Bone Miner       Date:  1986-02

9.  Zoledronic acid affects over-angiogenic phenotype of endothelial cells in patients with multiple myeloma.

Authors:  Claudio Scavelli; Giulia Di Pietro; Teresa Cirulli; Mauro Coluccia; Angela Boccarelli; Teresa Giannini; Giuseppe Mangialardi; Raffaello Bertieri; Addolorata Maria Luce Coluccia; Domenico Ribatti; Franco Dammacco; Angelo Vacca
Journal:  Mol Cancer Ther       Date:  2007-12       Impact factor: 6.261

Review 10.  Bisphosphonate mechanism of action.

Authors:  Alfred A Reszka; Gideon A Rodan
Journal:  Curr Rheumatol Rep       Date:  2003-02       Impact factor: 4.686

View more
  19 in total

1.  Bisphosphonates modulate the expression of OPG and M-CSF in hMSC-derived osteoblasts.

Authors:  Joo-Young Ohe; Yong-Dae Kwon; Hyeon-Woo Lee
Journal:  Clin Oral Investig       Date:  2011-09-22       Impact factor: 3.573

2.  The outcome after surgical therapy of bisphosphonate-associated osteonecrosis of the jaw--results of a clinical case series with an average follow-up of 20 months.

Authors:  Philipp Stockmann; Moritz Burger; Cornelius von Wilmowsky; Tobias Ebker; Rainer Lutz; Anne Bauersachs; Emeka Nkenke; Friedrich Wilhelm Neukam; Falk Wehrhan
Journal:  Clin Oral Investig       Date:  2013-08-29       Impact factor: 3.573

3.  Treatment of stage II medication-related osteonecrosis of the jaw with necrosectomy and autologous bone marrow mesenchymal stem cells.

Authors:  Pit Jacob Voss; Akihiko Matsumoto; Esteban Alvarado; Rainer Schmelzeisen; Fabian Duttenhöfer; Philipp Poxleitner
Journal:  Odontology       Date:  2017-02-20       Impact factor: 2.634

4.  Primary wound closure after tooth extraction for prevention of medication-related osteonecrosis of the jaw in patients under denosumab.

Authors:  Akihiko Matsumoto; Masanori Sasaki; Rainer Schmelzeisen; Yukiko Oyama; Yoshihide Mori; Pit Jacob Voss
Journal:  Clin Oral Investig       Date:  2016-02-29       Impact factor: 3.573

5.  Immunoexpression of IGF1, IGF2, and osteopontin in craniofacial bone repair associated with autogenous grafting in rat models treated with alendronate sodium.

Authors:  Paulo Roberto Camati; Allan Fernando Giovanini; Hugo Eduardo de Miranda Peixoto; Cassiana Majewski Schuanka; Maria Cecília Giacomel; Melissa Rodrigues de Araújo; João César Zielak; Rafaela Scariot; Tatiana Miranda Deliberador
Journal:  Clin Oral Investig       Date:  2016-10-22       Impact factor: 3.573

6.  In vitro comparison of new bisphosphonic acids and zoledronate effects on human gingival fibroblasts viability, inflammation and matrix turnover.

Authors:  Marianna De Colli; Paolo Tortorella; Guya Diletta Marconi; Mariangela Agamennone; Cristina Campestre; Marilena Tauro; Amelia Cataldi; Susi Zara
Journal:  Clin Oral Investig       Date:  2015-12-22       Impact factor: 3.573

7.  Prevalence of bisphosphonate-associated osteonecrosis of the jaw after intravenous zoledronate infusions in patients with early breast cancer.

Authors:  Petra Rugani; Gero Luschin; Norbert Jakse; Barbara Kirnbauer; Uwe Lang; Stephan Acham
Journal:  Clin Oral Investig       Date:  2013-06-10       Impact factor: 3.573

8.  Osteo-radio-necrosis (ORN) and bisphosphonate-related osteonecrosis of the jaws (BRONJ): the histopathological differences under the clinical similarities.

Authors:  Konstantinos T Mitsimponas; Patrick Moebius; Kerstin Amann; Philipp Stockmann; Karl-Andreas Schlegel; Friedrich-Wilhelm Neukam; Falk Wehrhan
Journal:  Int J Clin Exp Pathol       Date:  2014-01-15

9.  Dental risk factors for osteonecrosis of the jaws: a CONDOR case-control study.

Authors:  A Barasch; J Cunha-Cruz; F Curro; T DeRouen; G H Gilbert; P Hujoel; M M Safford; D A Vena; A E Voinea-Griffin; H Wu
Journal:  Clin Oral Investig       Date:  2012-12-02       Impact factor: 3.573

Review 10.  Safety of drugs used in the treatment of osteoporosis.

Authors:  Cora McGreevy; David Williams
Journal:  Ther Adv Drug Saf       Date:  2011-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.